IBDEI1XF ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30774,0)
;;=R33.9^^123^1585^24
;;^UTILITY(U,$J,358.3,30774,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30774,1,3,0)
;;=3^Urinary Retention,Unspec
;;^UTILITY(U,$J,358.3,30774,1,4,0)
;;=4^R33.9
;;^UTILITY(U,$J,358.3,30774,2)
;;=^5019332
;;^UTILITY(U,$J,358.3,30775,0)
;;=D51.8^^123^1586^2
;;^UTILITY(U,$J,358.3,30775,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30775,1,3,0)
;;=3^Anemia,Vitamin B12 Deficiency
;;^UTILITY(U,$J,358.3,30775,1,4,0)
;;=4^D51.8
;;^UTILITY(U,$J,358.3,30775,2)
;;=^5002288
;;^UTILITY(U,$J,358.3,30776,0)
;;=D52.9^^123^1586^1
;;^UTILITY(U,$J,358.3,30776,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30776,1,3,0)
;;=3^Anemia,Folate Deficiency
;;^UTILITY(U,$J,358.3,30776,1,4,0)
;;=4^D52.9
;;^UTILITY(U,$J,358.3,30776,2)
;;=^5002293
;;^UTILITY(U,$J,358.3,30777,0)
;;=I10.^^123^1587^12
;;^UTILITY(U,$J,358.3,30777,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30777,1,3,0)
;;=3^Hypertension,Essential
;;^UTILITY(U,$J,358.3,30777,1,4,0)
;;=4^I10.
;;^UTILITY(U,$J,358.3,30777,2)
;;=^5007062
;;^UTILITY(U,$J,358.3,30778,0)
;;=I15.0^^123^1587^13
;;^UTILITY(U,$J,358.3,30778,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30778,1,3,0)
;;=3^Hypertension,Renovascular
;;^UTILITY(U,$J,358.3,30778,1,4,0)
;;=4^I15.0
;;^UTILITY(U,$J,358.3,30778,2)
;;=^5007071
;;^UTILITY(U,$J,358.3,30779,0)
;;=I13.11^^123^1587^8
;;^UTILITY(U,$J,358.3,30779,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30779,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
;;^UTILITY(U,$J,358.3,30779,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,30779,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,30780,0)
;;=I13.2^^123^1587^7
;;^UTILITY(U,$J,358.3,30780,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30780,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
;;^UTILITY(U,$J,358.3,30780,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,30780,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,30781,0)
;;=I70.1^^123^1587^3
;;^UTILITY(U,$J,358.3,30781,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30781,1,3,0)
;;=3^Atherosclerosis of Renal Artery
;;^UTILITY(U,$J,358.3,30781,1,4,0)
;;=4^I70.1
;;^UTILITY(U,$J,358.3,30781,2)
;;=^269760
;;^UTILITY(U,$J,358.3,30782,0)
;;=I77.3^^123^1587^2
;;^UTILITY(U,$J,358.3,30782,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30782,1,3,0)
;;=3^Arterial Fibromuscular Dysplasia
;;^UTILITY(U,$J,358.3,30782,1,4,0)
;;=4^I77.3
;;^UTILITY(U,$J,358.3,30782,2)
;;=^5007812
;;^UTILITY(U,$J,358.3,30783,0)
;;=E26.02^^123^1587^5
;;^UTILITY(U,$J,358.3,30783,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30783,1,3,0)
;;=3^Glucocorticoid-Remediable Aldosteronism
;;^UTILITY(U,$J,358.3,30783,1,4,0)
;;=4^E26.02
;;^UTILITY(U,$J,358.3,30783,2)
;;=^329904
;;^UTILITY(U,$J,358.3,30784,0)
;;=I12.9^^123^1587^14
;;^UTILITY(U,$J,358.3,30784,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30784,1,3,0)
;;=3^Hypertensive CKD Stage 1-4
;;^UTILITY(U,$J,358.3,30784,1,4,0)
;;=4^I12.9
;;^UTILITY(U,$J,358.3,30784,2)
;;=^5007066
;;^UTILITY(U,$J,358.3,30785,0)
;;=I12.0^^123^1587^15
;;^UTILITY(U,$J,358.3,30785,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30785,1,3,0)
;;=3^Hypertensive CKD Stage 5 or ESRD
;;^UTILITY(U,$J,358.3,30785,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,30785,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,30786,0)
;;=I13.0^^123^1587^6
;;^UTILITY(U,$J,358.3,30786,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XF 3790 printed Apr 09, 2024@21:43:30 Page 2
IBDEI1XF ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30774,0)
+2 ;;=R33.9^^123^1585^24
+3 ;;^UTILITY(U,$J,358.3,30774,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,30774,1,3,0)
+6 ;;=3^Urinary Retention,Unspec
+7 ;;^UTILITY(U,$J,358.3,30774,1,4,0)
+8 ;;=4^R33.9
+9 ;;^UTILITY(U,$J,358.3,30774,2)
+10 ;;=^5019332
+11 ;;^UTILITY(U,$J,358.3,30775,0)
+12 ;;=D51.8^^123^1586^2
+13 ;;^UTILITY(U,$J,358.3,30775,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,30775,1,3,0)
+16 ;;=3^Anemia,Vitamin B12 Deficiency
+17 ;;^UTILITY(U,$J,358.3,30775,1,4,0)
+18 ;;=4^D51.8
+19 ;;^UTILITY(U,$J,358.3,30775,2)
+20 ;;=^5002288
+21 ;;^UTILITY(U,$J,358.3,30776,0)
+22 ;;=D52.9^^123^1586^1
+23 ;;^UTILITY(U,$J,358.3,30776,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,30776,1,3,0)
+26 ;;=3^Anemia,Folate Deficiency
+27 ;;^UTILITY(U,$J,358.3,30776,1,4,0)
+28 ;;=4^D52.9
+29 ;;^UTILITY(U,$J,358.3,30776,2)
+30 ;;=^5002293
+31 ;;^UTILITY(U,$J,358.3,30777,0)
+32 ;;=I10.^^123^1587^12
+33 ;;^UTILITY(U,$J,358.3,30777,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,30777,1,3,0)
+36 ;;=3^Hypertension,Essential
+37 ;;^UTILITY(U,$J,358.3,30777,1,4,0)
+38 ;;=4^I10.
+39 ;;^UTILITY(U,$J,358.3,30777,2)
+40 ;;=^5007062
+41 ;;^UTILITY(U,$J,358.3,30778,0)
+42 ;;=I15.0^^123^1587^13
+43 ;;^UTILITY(U,$J,358.3,30778,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,30778,1,3,0)
+46 ;;=3^Hypertension,Renovascular
+47 ;;^UTILITY(U,$J,358.3,30778,1,4,0)
+48 ;;=4^I15.0
+49 ;;^UTILITY(U,$J,358.3,30778,2)
+50 ;;=^5007071
+51 ;;^UTILITY(U,$J,358.3,30779,0)
+52 ;;=I13.11^^123^1587^8
+53 ;;^UTILITY(U,$J,358.3,30779,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,30779,1,3,0)
+56 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
+57 ;;^UTILITY(U,$J,358.3,30779,1,4,0)
+58 ;;=4^I13.11
+59 ;;^UTILITY(U,$J,358.3,30779,2)
+60 ;;=^5007069
+61 ;;^UTILITY(U,$J,358.3,30780,0)
+62 ;;=I13.2^^123^1587^7
+63 ;;^UTILITY(U,$J,358.3,30780,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,30780,1,3,0)
+66 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
+67 ;;^UTILITY(U,$J,358.3,30780,1,4,0)
+68 ;;=4^I13.2
+69 ;;^UTILITY(U,$J,358.3,30780,2)
+70 ;;=^5007070
+71 ;;^UTILITY(U,$J,358.3,30781,0)
+72 ;;=I70.1^^123^1587^3
+73 ;;^UTILITY(U,$J,358.3,30781,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,30781,1,3,0)
+76 ;;=3^Atherosclerosis of Renal Artery
+77 ;;^UTILITY(U,$J,358.3,30781,1,4,0)
+78 ;;=4^I70.1
+79 ;;^UTILITY(U,$J,358.3,30781,2)
+80 ;;=^269760
+81 ;;^UTILITY(U,$J,358.3,30782,0)
+82 ;;=I77.3^^123^1587^2
+83 ;;^UTILITY(U,$J,358.3,30782,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,30782,1,3,0)
+86 ;;=3^Arterial Fibromuscular Dysplasia
+87 ;;^UTILITY(U,$J,358.3,30782,1,4,0)
+88 ;;=4^I77.3
+89 ;;^UTILITY(U,$J,358.3,30782,2)
+90 ;;=^5007812
+91 ;;^UTILITY(U,$J,358.3,30783,0)
+92 ;;=E26.02^^123^1587^5
+93 ;;^UTILITY(U,$J,358.3,30783,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,30783,1,3,0)
+96 ;;=3^Glucocorticoid-Remediable Aldosteronism
+97 ;;^UTILITY(U,$J,358.3,30783,1,4,0)
+98 ;;=4^E26.02
+99 ;;^UTILITY(U,$J,358.3,30783,2)
+100 ;;=^329904
+101 ;;^UTILITY(U,$J,358.3,30784,0)
+102 ;;=I12.9^^123^1587^14
+103 ;;^UTILITY(U,$J,358.3,30784,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,30784,1,3,0)
+106 ;;=3^Hypertensive CKD Stage 1-4
+107 ;;^UTILITY(U,$J,358.3,30784,1,4,0)
+108 ;;=4^I12.9
+109 ;;^UTILITY(U,$J,358.3,30784,2)
+110 ;;=^5007066
+111 ;;^UTILITY(U,$J,358.3,30785,0)
+112 ;;=I12.0^^123^1587^15
+113 ;;^UTILITY(U,$J,358.3,30785,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,30785,1,3,0)
+116 ;;=3^Hypertensive CKD Stage 5 or ESRD
+117 ;;^UTILITY(U,$J,358.3,30785,1,4,0)
+118 ;;=4^I12.0
+119 ;;^UTILITY(U,$J,358.3,30785,2)
+120 ;;=^5007065
+121 ;;^UTILITY(U,$J,358.3,30786,0)
+122 ;;=I13.0^^123^1587^6
+123 ;;^UTILITY(U,$J,358.3,30786,1,0)
+124 ;;=^358.31IA^4^2
